Learn about the Stock Drop Intelligence Agent

Every week, markets move. Understanding why a stock dropped matters just as much as knowing that it dropped. This agent automates that research pipeline with a strict focus on precision and cost-efficiency.

Deterministic Filtering

Rather than sending broad queries to an AI, the agent starts with the numbers. It pulls 5-day closing prices for every tracked ticker from standard financial data providers and ranks them by percentage change. Only the worst-performing stocks with confirmed negative returns advance to the next stage, which eliminates guesswork and unnecessary processing costs.

Headline Triage

For each declining stock, the agent fetches raw RSS headlines from public news feeds. It only pulls the titles rather than full article content. These lightweight strings are sent to an AI model with a strict prompt to identify the top headlines most likely to explain a short-term price drop. Because headlines use very little text, this step costs a fraction of what full-article analysis would. Generic price trackers, standard institutional filings, and positive news are filtered out before a single full article is ever downloaded.

Targeted Deep Analysis

Only the selected headlines have their full article text extracted and scraped. That specific content is then passed to the AI to produce a concise summary for each article, along with a synthesized conclusion explaining the broader picture behind the stock's decline.

The Final Report

The result is a fully rendered HTML report that requires zero manual research. Each falling stock gets its own card showing the drop, the relevant headlines, individual article summaries, and an overall analyst-style conclusion. The entire process is generated automatically at a minimal token cost every time it runs.

Stocks in this report

Apple Inc.
AAPL
Performance (5d) ↘ -10.78%
Apple Inc. $AAPL Stock Holdings Cut by Clifford Swan Investment Counsel LLC - MarketBeat Apple reported record June-quarter revenue of $109.4 billion (up 16.4% YoY) and … Read more ▾ Collapse ▴
Apple reported record June-quarter revenue of $109.4 billion (up 16.4% YoY) and EPS of $2.02, exceeding expectations, with strong iPhone and Mac revenue growth. Despite positive earnings, institutional investors showed mixed sentiment with Clifford Swan cutting holdings by 3.0%, though other funds like Heartland Bank and FSA Advisors increased positions. Analysts remain constructive with TD Cowen raising its price target to $400 and the company maintaining a capital-efficient AI strategy.
AAPL Stock Slides Nearly 10% — Apple’s Earnings Divide Wall Street, But Retail Sees A Buying Opportunity - TradingView Apple's stock fell nearly 10% following weaker-than-expected fourth-quarter reve … Read more ▾ Collapse ▴
Apple's stock fell nearly 10% following weaker-than-expected fourth-quarter revenue guidance, with Wall Street divided on near-term versus long-term prospects. Key headwinds cited by analysts include supply constraints, rising memory costs, and margin pressure, though some firms like TD Cowen and Wells Fargo raised price targets citing long-term growth opportunities. Retail traders viewed the post-earnings decline as a buying opportunity, turning bullish on the stock despite the selloff.

Apple's recent stock decline of nearly 10% stems primarily from weaker-than-expected fourth-quarter revenue guidance and near-term operational headwinds including supply constraints, memory cost inflation, and margin pressures that are offsetting strong current product demand. While the company delivered record earnings with robust iPhone and Mac revenue growth, investors are concerned about how these cost pressures will impact future gross margins and the iPhone 18 pricing strategy. Wall Street remains divided, with some analysts raising price targets based on long-term growth catalysts (AI, 2nm chips, Services), while others like UBS turned cautious citing limited near-term upside. The market appears to be repricing the stock to reflect these near-term challenges despite the company's solid fundamental performance and long-term prospects.

Eli Lilly and Company
LLY
Performance (5d) ↘ -8.13%

No relevant articles found.

No summary available.

QUALCOMM Incorporated
QCOM
Performance (5d) ↘ -6.94%
Qualcomm Misses Q3 Earnings Estimates, Revenues Beat on Auto Growth - TradingView Qualcomm reported Q3 fiscal 2026 earnings of $2.21 per share, missing estimates … Read more ▾ Collapse ▴
Qualcomm reported Q3 fiscal 2026 earnings of $2.21 per share, missing estimates by 0.5%, though revenues of $9.95 billion beat consensus by 2.4%. Handset revenues plunged 20% due to OEM inventory drawdowns and memory supply constraints, but this was partially offset by record automotive sales growth of 61% and 9% IoT growth. Margin compression resulted from higher input costs across manufacturing, assembly, and materials, with QCT EBT margin contracting 4 percentage points to 26%.
Qualcomm's Near-Term Visibility 'Cloudy' As ASIC Ramp, Apple Roll-Off Weigh on Margins - Sahm Analysts cut Qualcomm price targets following earnings, with BofA Securities red … Read more ▾ Collapse ▴
Analysts cut Qualcomm price targets following earnings, with BofA Securities reducing its target from $220 to $180 and Rosenblatt Securities lowering from $265 to $235, citing near-term visibility concerns. Key headwinds include faster-than-expected Apple product revenue exits, lower-margin data center ASIC ramp, rising manufacturing costs, and continued consumer weakness in IoT. Analysts noted that Qualcomm's pricing actions will require several quarters to offset these margin pressures, with stock trading down 2.63% on the news.

Qualcomm's stock declined due to a combination of near-term margin pressures and visibility concerns that outweighed revenue beat expectations. While the company demonstrated strength in automotive and IoT segments, severe handset weakness and rising input costs compressed profitability, with EPS missing estimates. Analyst downgrades reflected concerns about faster Apple revenue declines and lower-margin data center ASIC revenues entering the mix, with margin recovery expected to take multiple quarters. The market's focus shifted from growth opportunities to near-term earnings headwinds, resulting in significant price target reductions across major analyst firms.

AbbVie Inc.
ABBV
Performance (5d) ↘ -6.88%
AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat - benzinga.com AbbVie beat Q2 earnings expectations with adjusted EPS of $3.65 (vs. $3.60 conse … Read more ▾ Collapse ▴
AbbVie beat Q2 earnings expectations with adjusted EPS of $3.65 (vs. $3.60 consensus) and revenue of $16.99B (vs. $16.765B estimate), representing strong year-over-year growth of 22.9% and 10.2% respectively. However, the company trimmed full-year earnings guidance to $13.87-$14.07 from $13.91-$14.11, primarily due to the $10.9B Apogee Therapeutics acquisition expected to close in Q3, which will reduce 2026 earnings by 14 cents per share, offsetting only a 10-cent operational improvement.
AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal - Yahoo Finance Analyst views on the Apogee acquisition are mixed, with bulls like Canaccord and … Read more ▾ Collapse ▴
Analyst views on the Apogee acquisition are mixed, with bulls like Canaccord and Piper Sandler raising price targets citing strong immunology and IBD pipeline opportunities, while bears including TD Cowen and Clear Street question whether the $10.9B price is justified given execution risks, competitive pressure from players like Regeneron, and uncertainty around long-term value capture in the crowded atopic dermatitis market. AbbVie's fair value model remains unchanged at $253.55 per share despite the deal announcement.

AbbVie's stock decline stems primarily from a disappointing earnings guidance reduction that overshadowed strong Q2 operational results. The $10.9B acquisition of Apogee Therapeutics, while strategically adding immunology assets in atopic dermatitis and asthma, is creating near-term earnings headwinds and raising concerns among analysts about execution risk and competitive intensity in an increasingly crowded market. The combination of reduced forward guidance, acquisition-related dilution, and mixed analyst sentiment regarding the deal's value proposition has pressured investor confidence despite the company's solid underlying business performance.

Philip Morris International Inc
PM
Performance (5d) ↘ -6.37%
Sapient Capital LLC Cuts Stake in Philip Morris International Inc. $PM - MarketBeat Sapient Capital LLC reduced its Philip Morris International holdings by 6.2% in … Read more ▾ Collapse ▴
Sapient Capital LLC reduced its Philip Morris International holdings by 6.2% in Q1, though the company reported strong Q2 earnings with $2.20 EPS beating estimates and 10.4% revenue growth. Despite mixed institutional activity, PM maintains a $297.9 billion market cap with a 27.46 PE ratio and recently increased its quarterly dividend to $1.47 per share.
Philip Morris International Inc Stock (PM) Moved Down by 3.21% on Jul 30: What Signal Does It Send? - TradingKey Philip Morris International stock declined 3.21% on July 30, underperforming the … Read more ▾ Collapse ▴
Philip Morris International stock declined 3.21% on July 30, underperforming the Food & Beverages sector amid investor concerns about smoke-free product margin sustainability and regulatory headwinds in nicotine pouches. The selloff was driven by capital expenditure pressures on free cash flow, potential European excise tax proposals, currency headwinds from a strengthening dollar, and institutional portfolio rebalancing as investors seek higher risk-adjusted returns.

Philip Morris International's recent stock decline reflects a market reassessment of near-term operational challenges despite strong earnings fundamentals. Key concerns include margin pressure from the capital-intensive transition to smoke-free products, regulatory risks including potential excise taxes in Europe and restrictions on nicotine pouches, and currency translation headwinds from dollar strength. Additionally, the stock's premium valuation tied to growth prospects has made it vulnerable to profit-taking as investors rotate toward higher-yielding opportunities amid shifting macroeconomic conditions. While the company's long-term strategic pivot remains intact, the market is currently prioritizing near-term margin stability and regulatory clarity over future growth potential.